NEUROCRINE BIOSCIENCES INC
Company Stats
- Market Cap
- $14.4B
- as of Sep 30, 2026
- Shares Outstanding
- 101.6M
- Free Float
- 93.0%
Income Statement
- Revenue
- $2.9B
- Operating Income
- $619.1M
- Net Income
- $478.6M
- EBITDA
- $645.1M
- Revenue Growth, 3Y
- 24.3%
- FCF Margin, 3Y Avg
- 23.0%
- FCF Margin, Worst Year
- 19.2%
Cash Flow
- Free Cash Flow
- $748.7M
- FCF Yield
- 5.2%
- Owner FCF Yield
- 3.7%
Balance Sheet
- Cash & Equivalents
- $713.0M
Returns & Capital
- Share Repurchases
- $167.7M
- Buyback Yield, 3Y Avg
- 1.1%
- SBC, 3Y Avg
- $202.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $2.9B | $748.7M | 26.2% |
| FY2024 | $2.4B | $557.2M | 23.7% |
| FY2023 | $1.9B | $361.6M | 19.2% |
| FY2022 | $1.5B | $322.9M | 21.7% |
| FY2021 | $1.1B | $233.1M | 20.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back